Abiraterone Acetate Withdrawal Syndrome: Does It Exist

Case Reports in Oncology

关键词: Abiraterone;    Withdrawal syndrome;    Prostate cancer;    Castrate-resistant prostate cancer;   

DOI  :  10.1159/000341564

来源: DOAJ

【 摘 要 】

In 2011 abiraterone acetate (AA) was approved for the treatment of castrate-resistant metastatic prostate cancer patients who have failed docetaxel chemotherapy. We report the case of a patient who experienced a confirmed PSA decrease of ≥50% after stopping AA, mimicking an antiandrogen withdrawal syndrome.

【 授权许可】

Unknown